Enantiomer-specific pharmacokineticsTUCKER, G. T.Acta pharmaceutica nordica. 1990, Vol 2, Num 3, pp 193-197, issn 1100-1801Article

Advances in understanding drug metabolism and its contribution to variability in patient responseTUCKER, G. T.Therapeutic drug monitoring. 2000, Vol 22, Num 1, pp 110-113, issn 0163-4356Article

Chirality and pharmacokineticsTUCKER, G. T.Pharmaceutical medicine (Basingstoke). 1992, Vol 6, Num 3, pp 231-240, issn 0265-0673Article

A clinical pharmacologist's perpectiveTUCKER, G. T.Biochemical Society transactions. 1991, Vol 19, Num 2, pp 460-462, issn 0300-5127, 3 p.Conference Paper

The software design quality reviewHOSEIN FALLAH; TUCKER, G. T.AT&T technical journal. 1987, Vol 66, Num 2, pp 40-49, issn 8756-2324Article

Journal impact factors : a 'bioequivalence' issue?ROSTAMI-HODJEGAN, A; TUCKER, G. T.British journal of clinical pharmacology. 2001, Vol 51, Num 2, pp 111-117, issn 0306-5251Article

A rare G₂₀₆₁ insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotypeMAREZ-ALLORGE, D; ELLIS, S. W; GUIDICE, J.-M. L et al.Pharmacogenetics (London). 1999, Vol 9, Num 3, pp 393-396, issn 0960-314XArticle

Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6LIN, L. Y; DI STEFANO, E. W; SCHMITZ, D. A et al.Drug metabolism and disposition. 1997, Vol 25, Num 9, pp 1059-1064, issn 0090-9556Article

The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humansPEACEY, S. R; ROSTAMI-HODJEGAN, A; GEORGE, E et al.The Journal of clinical endocrinology and metabolism. 1997, Vol 82, Num 5, pp 1458-1461, issn 0021-972XArticle

An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat : relevance to its use as a model of the CYP2D6 poor metaboliser phenotypeBARHAM, H. M; LENNARD, M. S; TUCKER, G. T et al.Biochemical pharmacology. 1994, Vol 47, Num 8, pp 1295-1307, issn 0006-2952Article

Plasma concentrations of bupivacaine after supraclavicular brachial plexus blockade in patients with chronic renal failureRICE, A. S. C; PITHER, C. E; TUCKER, G. T et al.Anaesthesia. 1991, Vol 46, Num 5, pp 354-357, issn 0003-2409, 4 p.Article

Inhibition of metroprolol metabolism by chloroquine and other antimalarial drugsLANCASTER, D. L; ADIO, R. A; TAI, K. K et al.Journal of pharmacy and pharmacology. 1990, Vol 42, Num 4, pp 267-271, issn 0022-3573, 5 p.Article

Stereoselective metabolism of metoprolol in Caucasians and Nigerians ― relationship to debrisoquine oxidation phenotypeLENNARD, M. S; TUCKER, G. T; WOODS, H. F et al.British journal of clinical pharmacology. 1989, Vol 27, Num 5, pp 613-616, issn 0306-5251Article

Disposition kinetics of ropivacaine in humansLEE, A; FAGAN, D; LAMONT, M et al.Anesthesia and analgesia. 1989, Vol 69, Num 6, pp 736-738, issn 0003-2999, 3 p.Article

Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism ― hypothesis testingJACKSON, P. R; TUCKER, G. T; WOODS, H. F et al.British journal of clinical pharmacology. 1989, Vol 28, Num 6, pp 655-662, issn 0306-5251Article

Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasiaMERZA, Z; ROSTAMI-HODJEGAN, A; MEMMOTT, A et al.Clinical endocrinology (Oxford. Print). 2006, Vol 65, Num 1, pp 45-50, issn 0300-0664, 6 p.Article

Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibitionMOGHADAMNIA, A. A; ROSTAMI-HODJEGAN, A; ABDUL-MANAP, R et al.British journal of clinical pharmacology. 2003, Vol 56, Num 1, pp 57-67, issn 0306-5251, 11 p.Article

First principles investigation of singly reduced cytochrome P450SEGALL, M. D; PAYNE, M. C; ELLIS, S. W et al.Xenobiotica (London. Print). 1999, Vol 29, Num 6, pp 561-571, issn 0049-8254Article

Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expressionSCHULZ-UTERMOEHL, T; BENNETT, A. J; ELLIS, S. W et al.Pharmacogenetics (London). 1999, Vol 9, Num 3, pp 357-366, issn 0960-314XArticle

Population pharmacokinetics of methadone in opiate users : characterization of time-dependent changesROSTAMI-HODJEGAN, A; WOLFF, K; HAY, A. W. M et al.British journal of clinical pharmacology. 1999, Vol 48, Num 1, pp 43-52, issn 0306-5251Article

Population-based modeling to demonstrate extrapancreatic effects of tolbutamideROSTAMI-HODJEGAN, A; PEACEY, S. R; GEORGE, E et al.American journal of physiology. Endocrinology and metabolism. 1998, Vol 37, Num 4, pp E758-E771, issn 0193-1849Article

The pharmacokinetics of methadone in healthy subjects and opiate usersWOLFF, K; ROSTAMI-HODJEGAN, A; SHIRES, S et al.British journal of clinical pharmacology. 1997, Vol 44, Num 4, pp 325-334, issn 0306-5251Article

Caffeine urinary metabolite ratios as markers of enzyme activity : a theoretical assessmentROSTAMI-HODJEGAN, A; NURMINEN, S; JACKSON, P. R et al.Pharmacogenetics (London). 1996, Vol 6, Num 2, pp 121-149, issn 0960-314XArticle

Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolitesCHING, M. S; BLAKE, C. L; GHABRIAL, H et al.Biochemical pharmacology. 1995, Vol 50, Num 6, pp 833-837, issn 0006-2952Article

Characterization of metronidazole metabolism by human liver microsomesLOFT, S; OTTON, S. V; LENNARD, M. S et al.Biochemical pharmacology. 1991, Vol 41, Num 8, pp 1127-1134, issn 0006-2952, 8 p.Article